Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib

• Koichi Azuma ,

  * E-mail: azuma@med.kurume-u.ac.jp

  Affiliation Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan

  ⨯
• Nobukazu Komatsu,

  Affiliation Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan

  ⨯
• Satoshi Hattori,

  Affiliation Biostatistics Center, Kurume University, Kurume, Fukuoka, Japan

  ⨯
• Satoko Matsueda,

  Affiliation Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan

  ⨯
• Akihiko Kawahara,

  Affiliation Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka, Japan

  ⨯
• Tetsuro Sasada,

  Affiliation Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan

  ⨯
• Kyogo Itoh,

  Affiliation Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan

  ⨯
• Tomoaki Hoshino

  Affiliation Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan

  ⨯